Compare Core Scientific Inc (CORZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Zimmer Biomet Holdings Inc — how do they compare? Core Scientific Inc trades at $15.41 (market cap $4.94B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.4× Core Scientific Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CORZ | ZBH | |
|---|---|---|
Market Cap | $4.94B | $16.95B |
Volume | 15,630,800 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $29.16 | $103.98 |
52-Week Low | $13.57 | $79.58 |
Typical Hold Time | 20 Days | 89 Days |
Enterprise Value | $7.46B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.36, down 3.64% on the day, with bearish technical signals and negative earnings momentum. The company reported a net loss of $288.62 million in 2025 with revenue of $319.02 million, resulting in a -324.9% net income margin. Despite financial challenges, analyst sentiment remains overwhelmingly positive with 19 buy ratings and a $32.75 consensus price target, representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with strong Wall Street support but substantial fundamental challenges. Positive catalysts include the AI data center transition and insider buying, while risks include persistent losses, heavy capital expenditures, and competitive pressures in the digital infrastructure space.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
